title: Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog).
abstract: A group of 13 acromegalic patients was treated with lanreotide for 18 months and followed-up echocardiographically; these patients showed significant correlations between the decrease of both growth hormone (GH) and insulin-like growth factor-1 and the decrease of left ventricular mass index. This documents a regression of left ventricular hypertrophy in acromegaly after lanreotide treatment, the degree of which is dependent on the magnitude of the decrease of GH and insulin-like growth factor-1 serum levels.
authors.affiliation: Third Department of Medicine, Charles University, Prague, Czech Republic.
authors.forename: J
authors.initials: J
authors.lastname: Hradec
authors.forename: J
authors.initials: J
authors.lastname: Kral
authors.forename: T
authors.initials: T
authors.lastname: Janota
authors.forename: M
authors.initials: M
authors.lastname: Krsek
authors.forename: V
authors.initials: V
authors.lastname: Hana
authors.forename: J
authors.initials: J
authors.lastname: Marek
authors.forename: M
authors.initials: M
authors.lastname: Malik
mesh_terms: D000172:Acromegaly / Q000150:complications / Q000188:drug therapy*; D000328:Adult; D005260:Female; D006321:Heart / Q000187:drug effects; D006331:Heart Diseases / Q000188:drug therapy* / Q000209:etiology; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011446:Prospective Studies; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D006727:Hormone Antagonists; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin